Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion Recommending Approval of Empliciti Plus Pomalidomide and Low-Dose Dexamethasone for Treatment of Patients with R/R MM
Tweet Send to a Friend
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
